If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
400.00    0.00 (0.00%)
Bid:
395.00
Ask:
405.00
Spread: 10.00 (2.532%)
Market Cap: £191.99m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Investor results presentation

21 Aug 2019 07:00

RNS Number : 6759J
Tristel PLC
21 August 2019
 

21 August 2019 

Tristel plc 

("Tristel" or the "Company") 

 

Investor results presentation 

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, will announce the Company's full year results for the year ended 30 June 2019 on Wednesday 16 October 2019.

 

Investor presentations 

Paul Swinney, CEO, and Liz Dixon, CFO, will present the Company's results in two separate events open to all investors. The same presentation will be given at both events which are being held at different times to offer convenient options for those wishing to attend. 

 

Two presentations will take place on Wednesday 16 October 2019 at the following times and location: 

·; 10.30 for a 10.45 start at The Brand Exchange, 3 Birchin Ln, London, EC3V 9BW 

·; 16.45 for a 17.00 start at No. 1 Cornhill, London, EC3V 3ND

 

The presentations will be followed by refreshments.  

 

If you would like to register for either investor presentation, or require further information, please contact Lianne Cawthorne at Walbrook PR on 020 7933 8780 or email tristel@walbrookpr.com ensuring you detail in your email which presentation you would like to attend. 

 

The results presentation will be made available on the Company's website www.tristel.com on the day of results. 

 

 

For further information please contact:  

 

 

Tristel plc 

Tel: 01638 721 500 

Paul Swinney, Chief Executive Officer 

Liz Dixon, Finance Director 

Walbrook PR Ltd 

Tel: 020 7933 8780 or tristel@walbrookpr.com 

Paul McManus 

Mob: 07980 541 893 

Lianne Cawthorne 

Mob: 07584 391 303 

finnCap 

Geoff Nash/ Giles Rolls (Corporate Finance) 

Tel: 020 7220 0500 

Alice Lane (ECM) 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAURSORKKAWUAR
Date   Source Headline
2nd Oct 202311:50 amRNSHolding(s) in Company
28th Sep 20232:00 pmRNSExercise of Share Options and Total Voting Rights
26th Sep 20232:40 pmRNSHolding(s) in Company
25th Sep 20238:40 amRNSHolding(s) in Company
22nd Sep 20233:40 pmRNSHolding(s) in Company
12th Sep 20237:00 amRNSNotice of Results
4th Sep 20237:00 amRNSHealth Canada regulatory approval submission
31st Jul 20238:05 amRNSHolding(s) in Company
28th Jul 20238:28 amRNSDirector/PDMR Shareholding
25th Jul 20237:00 amRNSTrading update
12th Jul 20237:00 amRNSShareholder Open Day and Notice of Trading Update
10th Jul 20237:00 amRNSExercise of Share Options and Total Voting Rights
26th Jun 20237:00 amRNSDirector/PDMR Shareholding
22nd Jun 20234:01 pmRNSHolding(s) in Company
16th Jun 20237:00 amRNSExercise of Share Options and Total Voting Rights
14th Jun 20234:10 pmRNSHolding(s) in Company
6th Jun 20235:00 pmRNSExercise of Share Options and Total Voting Rights
5th Jun 202310:00 amRNSAnalyst and Investor presentation
5th Jun 20237:00 amRNSFDA De Novo approval
28th Mar 202311:30 amRNSIssue of Equity
27th Mar 20237:00 amRNSSuccessful submission of additional data to US FDA
14th Mar 20232:05 pmRNSSecond Price Monitoring Extn
14th Mar 20232:00 pmRNSPrice Monitoring Extension
14th Mar 20239:30 amRNSIssue of Equity
22nd Feb 20234:30 pmRNSIssue of Equity
20th Feb 20237:00 amRNSHalf-year Report
30th Jan 20237:00 amRNSNotice of Results and Investor presentation
14th Dec 202211:00 amRNSResult of AGM - Replacement
13th Dec 20227:00 amRNSIssue of Equity
12th Dec 202211:26 amRNSResult of AGM
12th Dec 20227:00 amRNSAGM Statement
2nd Nov 20221:50 pmRNSHolding(s) in Company
25th Oct 20227:00 amRNSAudited Preliminary Results
6th Oct 20229:15 amRNSIssue of Equity
4th Oct 202212:00 pmRNSAppointment of new Company Secretary
4th Oct 20227:00 amRNSNotice of Results & Investor Presentation
29th Sep 20221:00 pmRNSNorth America update
30th Aug 20227:00 amRNSHolding(s) in Company
22nd Jul 20221:05 pmRNSDirector/PDMR Shareholding
21st Jul 202210:15 amRNSHolding(s) in Company
18th Jul 20224:41 pmRNSSecond Price Monitoring Extn
18th Jul 20224:35 pmRNSPrice Monitoring Extension
18th Jul 20227:00 amRNSTrading update and special dividend
30th Jun 20227:00 amRNSDe Novo FDA submission for Tristel Duo ULT
20th Jun 202210:00 amRNSShareholder Open Day & Notice of Trading update
7th Jun 20221:15 pmRNSHolding(s) in Company
4th May 20227:00 amRNSInvestor Presentation
3rd May 202212:30 pmRNSHolding(s) in Company
14th Apr 202212:00 pmRNSIssue of Equity
6th Apr 202212:10 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.